
|Podcasts|January 14, 2022
Pharmacy Focus: Psychedelic Pharmacy - Episode 3
Colonel Dallas Hack discussed the development of a novel derivative of psilocybin for the treatment of post-traumatic stress disorder
Advertisement
In this episode, Colonel Dallas Hack discussed the development of a novel derivative of psilocybin for the treatment of post-traumatic stress disorder, as well as how his own background led him to this research. In the interview, Hack said he believes a derivative could improve access as well as acceptance of the psychedelic drug.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Early Recognition and Routine Discussion: Improving Outcomes in Tardive Dyskinesia
2
Meet the FDA’s Newly Approved OTC Sunscreen Ingredient: Bemotrizinol
3
Do GLP-1 Receptor Agonists Increase the Risk of Smell and Taste Disturbances?
4
Targeting CSF1R in TGCT: Evaluating the Evidence and Empowering Pharmacist-Led Care
5










































































































